​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions


GILD Stock Forecast


Gilead Sciences stock forecast is as follows: an average price target of $88.11 (represents a -3.61% downside from GILD’s last price of $91.41) and a rating consensus of 'Buy', based on 23 wall street analysts offering a 1-year stock forecast.

GILD Price Target


The average price target for Gilead Sciences (GILD) is $88.11 based on 1-year price targets from 23 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $71.00. This represents a potential -3.61% downside from GILD's last price of $91.41.

GILD Analyst Ratings


Buy

According to 23 Wall Street analysts, Gilead Sciences's rating consensus is 'Buy'. The analyst rating breakdown for GILD stock is 0 'Strong Buy' (0.00%), 15 'Buy' (65.22%), 7 'Hold' (30.43%), 1 'Sell' (4.35%), and 0 'Strong Sell' (0.00%).

Gilead Sciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Joseph CatanzaroPiper Sandler$105.00$90.0916.55%14.87%
Oct 21, 2024Evan David SeigermanBMO Capital$94.00$86.119.16%2.83%
Oct 21, 2024Andrew BerensLeerink Partners$96.00$86.7210.70%5.02%
Oct 18, 2024Terence FlynnMorgan Stanley$84.00$87.07-3.53%-8.11%
Sep 23, 2024Michael YeeJefferies$95.00$83.7613.42%3.93%
Sep 12, 2024Salveen RichterGoldman Sachs$71.00$82.85-14.30%-22.33%
Sep 12, 2024Terence FlynnMorgan Stanley$79.00$82.63-4.39%-13.58%
Sep 11, 2024Joseph CatanzaroPiper Sandler$95.00$79.9318.85%3.93%
Aug 14, 2024Asthika GoonewardeneTruist Financial$83.00$74.1411.95%-9.20%
Aug 09, 2024Evan David SeigermanBMO Capital$85.00$75.5912.45%-7.01%
Aug 09, 2024Brian AbrahamsRBC Capital$72.00$75.59-4.75%-21.23%
Jul 08, 2024Steven SeedhouseRaymond James$93.00$67.7637.25%1.74%
Jun 24, 2024Michael YeeJefferies$85.00$71.2419.31%-7.01%
Jun 20, 2024Brian SkorneyRobert W. Baird$80.00$69.2115.59%-12.48%
Jun 17, 2024Salim SyedMizuho Securities$90.00$64.5239.50%-1.54%
Jun 14, 2024Brian AbrahamsRBC Capital$74.00$64.6814.41%-19.05%
May 20, 2024Evan David SeigermanBMO Capital$80.00$67.9017.82%-12.48%
Apr 24, 2024Morten HerholdtHSBC$69.00$67.082.86%-24.52%
Feb 14, 2024Brian AbrahamsRBC Capital$76.00$73.533.36%-16.86%
Sep 27, 2023Brian AbrahamsRBC Capital$84.00$75.9010.67%-8.11%
Sep 08, 2023Geoff MeachamBank of America Securities$95.00$75.9225.13%3.93%
Feb 03, 2023Leerink Partners$91.00$84.647.51%-0.45%
Feb 03, 2023Piper Sandler$112.00$81.3937.61%22.52%
Jan 03, 2023Wells Fargo$90.00$85.465.31%-1.54%
Dec 01, 2022Morgan Stanley$81.00$88.34-8.31%-11.39%
Oct 31, 2022Carter GouldBarclays$76.00$79.27-4.13%-16.86%
Oct 28, 2022Robyn KarnauskasTruist Financial$91.00$70.2029.63%-0.45%
Oct 28, 2022Brian SkorneyRobert W. Baird$69.00$79.27-12.96%-24.52%
Sep 15, 2022Truist Financial$76.00$64.8117.26%-16.86%
Sep 13, 2022Wells Fargo$74.00$66.1911.80%-19.05%
Jul 15, 2022Morgan Stanley$65.00$62.304.34%-28.89%
May 23, 2022David RisingerLeerink Partners$68.00$64.046.18%-25.61%
May 17, 2022Do KimPiper Sandler$69.00$63.189.21%-24.52%
Apr 29, 2022BMO Capital$63.00$59.545.81%-31.08%
Apr 29, 2022Piper Sandler$73.00$60.0421.59%-20.14%
Apr 06, 2022Do KimPiper Sandler$71.00$60.8216.74%-22.33%
Mar 31, 2022Mohit BansalWells Fargo$63.00$59.455.97%-31.08%
Mar 01, 2022Michael YeeJefferies$80.00$59.5034.45%-12.48%
Feb 24, 2022Colin BristowUBS$54.00$59.85-9.77%-40.93%
Feb 24, 2022Matthew HarrisonMorgan Stanley$69.00$59.8515.29%-24.52%
Feb 08, 2022Salim SyedMizuho Securities$75.00$63.7017.74%-17.95%
Feb 04, 2022Steve ChesneyAtlantic Equities$62.00$63.10-1.74%-32.17%
Feb 03, 2022Jason McCarthyMaxim Group$84.00$64.5730.09%-8.11%
Feb 03, 2022Hartaj SinghOppenheimer$90.00$64.5739.38%-1.54%
Jan 28, 2022David ToungArgus Research$75.00$67.9910.31%-17.95%
Dec 06, 2021Salveen RichterGoldman Sachs$80.00$67.9417.75%-12.48%
Nov 19, 2021Robert DriscollWedbush$67.00$67.14-0.21%-26.70%
Apr 29, 2021Cory KasimovJ.P. Morgan$74.00$61.1421.03%-19.05%

The latest Gilead Sciences stock forecast, released on Nov 07, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $105.00, which represents a 16.55% increase from the stock price at the time of the forecast ($90.09), and a 14.87% increase from GILD last price ($91.41).

Gilead Sciences Price Target by Period


1M3M12M
# Anlaysts-419
Avg Price Target-$94.75$84.53
Last Closing Price$91.41$91.41$91.41
Upside/Downside-100.00%3.65%-7.53%

In the current month, the average price target of Gilead Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gilead Sciences's last price of $91.41. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024CitigroupBuyInitialise
Oct 21, 2024BarclaysOverweightOverweightHold
Oct 21, 2024BernsteinOutperformOutperformHold
Oct 21, 2024Leerink PartnersOverweightOverweightHold
Oct 21, 2024Wells FargoSector PerformSector PerformHold
Oct 21, 2024RBC CapitalUnderperformUnderperformHold
Oct 21, 2024Leerink PartnersOutperformUpgrade
Oct 18, 2024Cowen & Co.BuyBuyHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 17, 2024BernsteinOutperformInitialise
Oct 07, 2024Wells FargoSector PerformOverweightUpgrade
Oct 07, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 04, 2024RBC CapitalSector PerformSector PerformHold
Sep 23, 2024BarclaysPositivePositiveHold
Sep 23, 2024JefferiesBuyBuyHold
Sep 20, 2024NeedhamHoldHoldHold
Sep 12, 2024Goldman SachsNeutralNeutralHold
Sep 12, 2024Morgan StanleyReduceReduceHold
Sep 12, 2024BMO CapitalOutperformOutperformHold
Sep 11, 2024Piper SandlerOverweightOverweightHold
Sep 04, 2024Raymond JamesUnderperformUnderperformHold
Aug 15, 2024Cowen & Co.BuyBuyHold
Aug 15, 2024RBC CapitalSector PerformSector PerformHold
Aug 09, 2024Goldman SachsNeutralNeutralHold
Aug 09, 2024BMO CapitalOutperformOutperformHold
Aug 09, 2024RBC CapitalOutperformOutperformHold
Jul 29, 2024Cantor FitzgeraldNeutralNeutralHold
Jul 22, 2024Raymond JamesUnderperformUnderperformHold
Jul 22, 2024RBC CapitalSector PerformSector PerformHold
Jul 08, 2024Raymond JamesOutperformUpgrade
Jun 24, 2024JefferiesBuyBuyHold
Jun 20, 2024BMO CapitalOutperformOutperformHold
Jun 14, 2024UBSSector PerformSector PerformHold
Jun 14, 2024RBC CapitalUnderperformUnderperformHold
Jun 14, 2024Evercore ISIOutperformOutperformHold
Jun 14, 2024RBC CapitalSector PerformSector PerformHold
May 20, 2024BMO CapitalOutperformOutperformHold
Apr 24, 2024HSBCHoldUpgrade
Apr 19, 2024Wells FargoSector PerformSector PerformHold
Feb 14, 2024Wells FargoEqual-WeightEqual-WeightHold
Sep 27, 2023BMO CapitalOutperformMarket PerformDowngrade
Sep 08, 2023Bank of America SecuritiesBuyUpgrade
May 16, 2023BMO CapitalMarket PerformOutperformUpgrade
Mar 10, 2023RBC CapitalSector PerformSector PerformHold
Feb 14, 2023BenchmarkBuyBuyHold
Feb 03, 2023SVB LeerinkMarket PerformMarket PerformHold
Feb 03, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Feb 03, 2023Piper SandlerOverweightOverweightHold
Jan 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Jan 03, 2023RBC CapitalSector PerformDowngrade
Dec 08, 2022Piper SandlerOverweightOverweightHold
Dec 01, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Nov 01, 2022SVB LeerinkMarket PerformMarket PerformHold
Oct 28, 2022WedbushOutperformInitialise
Oct 28, 2022NeedhamHoldHoldHold
Oct 28, 2022Piper SandlerNeutralOverweightUpgrade
Oct 05, 2022J.P. MorganBuyOverweightUpgrade
Oct 04, 2022Credit SuisseOutperformUpgrade
Oct 04, 2022NeedhamHoldInitialise
Oct 04, 2022J.P. MorganBuyUpgrade
Sep 13, 2022Wells FargoEqual-WeightEqual-WeightHold
Jul 26, 2022Piper SandlerNeutralNeutralHold
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 23, 2022SVB LeerinkMarket PerformInitialise
May 17, 2022Piper SandlerNeutralNeutralHold
Apr 29, 2022BMO CapitalMarket PerformMarket PerformHold
Apr 21, 2022Cowen & Co.OutperformOutperformHold
Apr 06, 2022Piper SandlerNeutralNeutralHold
Mar 31, 2022Wells FargoEqual-WeightEqual-WeightHold
Feb 28, 2022BMO CapitalMarket PerformDowngrade
Feb 26, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Feb 08, 2022Mizuho SecuritiesBuyBuyHold

Gilead Sciences's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its GILD rating from "null" to "Buy".

Gilead Sciences Financial Forecast


Gilead Sciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$7.12B$7.05B$6.60B$6.35B$7.39B$7.04B$6.26B$6.59B$7.24B$7.42B$6.22B$6.42B$7.42B$6.58B$5.14B$5.55B$5.88B$5.60B$5.68B$5.28B$5.09B$6.50B
Avg Forecast$7.56B$7.30B$6.87B$6.66B$7.16B$7.02B$6.70B$6.36B$7.10B$6.81B$6.45B$6.33B$6.64B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$5.74B$6.65B
High Forecast$7.75B$7.49B$7.05B$6.75B$7.43B$7.05B$6.70B$6.36B$7.27B$7.02B$6.62B$6.49B$6.85B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$6.89B$7.98B
Low Forecast$7.39B$7.14B$6.72B$6.58B$6.93B$6.98B$6.70B$6.36B$6.89B$6.63B$6.31B$6.19B$6.42B$6.13B$5.86B$6.29B$6.61B$6.29B$6.08B$6.74B$7.08B$6.29B$5.29B$5.45B$5.72B$5.61B$5.53B$5.30B$4.59B$5.32B
# Analysts33351579910211010139916101019131015998812161915
Surprise %--------1.00%1.04%1.02%1.00%1.11%1.15%1.07%1.05%1.10%1.18%1.02%0.95%1.05%1.05%0.97%1.02%1.03%1.00%1.03%1.00%0.89%0.98%

Gilead Sciences's average Quarter revenue forecast for Mar 24 based on 9 analysts is $6.36B, with a low forecast of $6.36B, and a high forecast of $6.36B. GILD's average Quarter revenue forecast represents a -10.65% decrease compared to the company's last Quarter revenue of $7.12B (Dec 23).

Gilead Sciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351579910211010139916101019131015998812161915
EBITDA--------$1.61B$2.62B$1.67B$2.01B$2.42B$3.11B$2.08B$86.00M$1.53B$4.23B$2.69B$3.06B$2.57B$2.59B$2.14B$2.59B$2.49B$-904.00M$3.01B$2.96B$2.68B$4.17B
Avg Forecast$2.47B$2.38B$2.24B$2.17B$2.33B$2.29B$2.19B$619.71M$2.32B$2.22B$2.10B$563.37M$2.38B$2.18B$2.08B$512.15M$2.35B$2.24B$2.16B$3.02B$2.52B$2.23B$1.88B$2.44B$2.03B$1.99B$1.97B$2.69B$2.98B$4.27B
High Forecast$2.53B$2.44B$2.30B$2.20B$2.42B$2.30B$2.19B$743.65M$2.37B$2.29B$2.16B$676.04M$2.86B$2.18B$2.08B$614.59M$2.35B$2.24B$2.16B$3.62B$2.52B$2.23B$1.88B$2.93B$2.03B$1.99B$1.97B$3.23B$3.58B$5.12B
Low Forecast$2.41B$2.33B$2.19B$2.14B$2.26B$2.28B$2.19B$495.77M$2.25B$2.16B$2.06B$450.70M$1.91B$2.18B$2.08B$409.72M$2.35B$2.24B$2.16B$2.41B$2.52B$2.23B$1.88B$1.95B$2.03B$1.99B$1.97B$2.15B$2.39B$3.41B
Surprise %--------0.70%1.18%0.79%3.57%1.01%1.43%1.00%0.17%0.65%1.89%1.24%1.01%1.02%1.16%1.14%1.06%1.23%-0.45%1.53%1.10%0.90%0.98%

9 analysts predict GILD's average Quarter EBITDA for Mar 24 to be $619.71M, with a high of $743.65M and a low of $495.77M. This is -61.56% lower than Gilead Sciences's previous annual EBITDA (Dec 23) of $1.61B.

Gilead Sciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351579910211010139916101019131015998812161915
Net Income--------$1.43B$2.18B$2.14B$1.01B$1.64B$1.79B$1.14B$12.00M$376.00M$2.59B$1.52B$1.73B$1.55B$360.00M$-3.35B$1.55B$2.70B$-1.17B$1.88B$1.98B$1.54B$2.70B
Avg Forecast$2.69B$2.60B$2.29B$2.20B$2.15B$1.92B$2.02B$19.05M$2.21B$2.40B$2.06B$17.32M$592.24M$1.78B$1.90B$15.75M$1.99B$2.20B$2.18B$1.74B$2.55B$2.44B$1.81B$1.45B$2.09B$2.18B$2.15B$1.79B$1.71B$2.76B
High Forecast$2.78B$2.69B$2.36B$2.29B$2.56B$1.96B$2.02B$22.86M$2.56B$2.62B$2.13B$20.78M$710.69M$1.78B$1.90B$18.90M$1.99B$2.20B$2.18B$2.08B$2.55B$2.44B$1.81B$1.74B$2.09B$2.18B$2.15B$2.15B$2.06B$3.31B
Low Forecast$2.61B$2.53B$2.22B$2.15B$1.46B$1.88B$2.01B$15.24M$1.99B$2.15B$2.00B$13.86M$473.80M$1.78B$1.90B$12.60M$1.99B$2.20B$2.18B$1.39B$2.55B$2.44B$1.81B$1.16B$2.09B$2.18B$2.15B$1.43B$1.37B$2.21B
Surprise %--------0.65%0.91%1.04%58.31%2.77%1.00%0.60%0.76%0.19%1.18%0.70%1.00%0.61%0.15%-1.85%1.07%1.29%-0.54%0.87%1.10%0.90%0.98%

Gilead Sciences's average Quarter net income forecast for Mar 24 is $19.05M, with a range of $15.24M to $22.86M. GILD's average Quarter net income forecast represents a -98.67% decrease compared to the company's last Quarter net income of $1.43B (Dec 23).

Gilead Sciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351579910211010139916101019131015998812161915
SG&A--------$1.61B$1.31B$1.85B$1.32B$2.02B$1.21B$1.36B$1.08B$1.65B$1.19B$1.35B$1.05B$1.73B$1.11B$1.24B$1.08B$1.20B$1.05B$1.09B$1.03B$997.00M$850.00M
Avg Forecast$1.56B$1.50B$1.41B$1.37B$1.47B$1.44B$1.38B$1.09B$1.46B$1.40B$1.33B$987.27M$2.56B$1.26B$1.20B$897.51M$1.36B$1.29B$1.25B$1.06B$1.45B$1.29B$1.09B$1.01B$1.17B$1.15B$1.14B$934.04M$1.11B$868.64M
High Forecast$1.60B$1.54B$1.45B$1.39B$1.53B$1.45B$1.38B$1.30B$1.50B$1.44B$1.36B$1.18B$3.07B$1.26B$1.20B$1.08B$1.36B$1.29B$1.25B$1.27B$1.45B$1.29B$1.09B$1.21B$1.17B$1.15B$1.14B$1.12B$1.33B$1.04B
Low Forecast$1.52B$1.47B$1.38B$1.35B$1.43B$1.44B$1.38B$868.79M$1.42B$1.36B$1.30B$789.81M$2.05B$1.26B$1.20B$718.01M$1.36B$1.29B$1.25B$848.04M$1.45B$1.29B$1.09B$806.32M$1.17B$1.15B$1.14B$747.23M$888.34M$694.91M
Surprise %--------1.10%0.94%1.39%1.34%0.79%0.96%1.13%1.21%1.21%0.92%1.08%1.00%1.19%0.86%1.14%1.07%1.03%0.91%0.96%1.10%0.90%0.98%

Gilead Sciences's average Quarter SG&A projection for Mar 24 is $1.09B, based on 9 Wall Street analysts, with a range of $868.79M to $1.30B. The forecast indicates a -32.46% fall compared to GILD last annual SG&A of $1.61B (Dec 23).

Gilead Sciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts33351579910211010139916101019131015998812161915
EPS--------$1.15$1.75$1.71$0.81$1.31$1.43$0.91$0.01$0.30$2.06$1.21$1.38$1.24$0.29$-2.67$1.23$2.13$-0.92$1.48$1.55$1.18$2.07
Avg Forecast$2.15$2.08$1.82$1.75$1.72$1.53$1.61$-1.49$1.76$1.92$1.64$1.52$1.52$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$1.86$2.33
High Forecast$2.22$2.14$1.88$1.83$2.04$1.56$1.61$-1.45$2.04$2.09$1.70$1.57$1.58$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$2.23$2.80
Low Forecast$2.08$2.01$1.77$1.71$1.16$1.50$1.61$-1.54$1.59$1.72$1.59$1.48$1.45$1.43$1.52$1.80$1.59$1.76$1.74$2.08$2.04$1.95$1.44$1.57$1.67$1.74$1.72$1.61$1.49$1.86
Surprise %--------0.65%0.91%1.04%0.53%0.86%1.00%0.60%0.01%0.19%1.17%0.70%0.66%0.61%0.15%-1.85%0.78%1.28%-0.53%0.86%0.96%0.63%0.89%

According to 9 Wall Street analysts, Gilead Sciences's projected average Quarter EPS for Mar 24 is $-1.49, with a low estimate of $-1.54 and a high estimate of $-1.45. This represents a -229.84% decrease compared to GILD previous annual EPS of $1.15 (Dec 23).

Gilead Sciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$99.14$135.8337.01%Buy
AZNAstraZeneca$66.25$88.0032.83%Buy
LLYEli Lilly and$781.98$1.03K31.39%Buy
AMGNAmgen$261.22$338.2229.48%Buy
PFEPfizer$26.59$32.7123.02%Hold
JNJJohnson & Johnson$144.19$175.1321.46%Buy
ABBVAbbVie$181.22$211.2016.54%Buy
GILDGilead Sciences$91.41$88.11-3.61%Buy
BMYBristol-Myers Squibb$56.57$50.50-10.73%Hold

GILD Forecast FAQ


Is Gilead Sciences a good buy?

Yes, according to 23 Wall Street analysts, Gilead Sciences (GILD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 65.22% of GILD's total ratings.

What is GILD's price target?

Gilead Sciences (GILD) average price target is $88.11 with a range of $71 to $105, implying a -3.61% from its last price of $91.41. The data is based on 23 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Gilead Sciences stock go up soon?

According to Wall Street analysts' prediction for GILD stock, the company can go down by -3.61% (from the last price of $91.41 to the average price target of $88.11), up by 14.87% based on the highest stock price target, and down by -22.33% based on the lowest stock price target.

Can Gilead Sciences stock reach $140?

GILD's average twelve months analyst stock price target of $88.11 does not support the claim that Gilead Sciences can reach $140 in the near future.

What are Gilead Sciences's analysts' financial forecasts?

Gilead Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $27.23B (high $27.54B, low $26.97B), average EBITDA is $7.43B (high $7.65B, low $7.22B), average net income is $6.1B (high $6.56B, low $5.36B), average SG&A $5.38B (high $5.66B, low $5.11B), and average EPS is $3.36 (high $3.76, low $2.72). GILD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.4B (high $29.04B, low $27.82B), average EBITDA is $9.26B (high $9.47B, low $9.07B), average net income is $9.78B (high $10.12B, low $9.5B), average SG&A $5.84B (high $5.97B, low $5.72B), and average EPS is $7.8 (high $8.07, low $7.58).

Did the GILD's actual financial results beat the analysts' financial forecasts?

Based on Gilead Sciences's last annual report (Dec 2023), the company's revenue was $27.12B, beating the average analysts forecast of $26.7B by 1.56%. Apple's EBITDA was $7.6B, beating the average prediction of $7.21B by 5.55%. The company's net income was $5.66B, missing the average estimation of $6.69B by -15.26%. Apple's SG&A was $6.09B, beating the average forecast of $5.18B by 17.65%. Lastly, the company's EPS was $4.54, missing the average prediction of $6.84 by -33.63%. In terms of the last quarterly report (Dec 2023), Gilead Sciences's revenue was $7.12B, beating the average analysts' forecast of $7.1B by 0.20%. The company's EBITDA was $1.61B, missing the average prediction of $2.32B by -30.39%. Gilead Sciences's net income was $1.43B, missing the average estimation of $2.21B by -35.19%. The company's SG&A was $1.61B, beating the average forecast of $1.46B by 10.09%. Lastly, the company's EPS was $1.15, missing the average prediction of $1.76 by -34.60%